Aggregation of tau protein is a pathological hallmark of Alzheimer’s disease and other neurodegenerative tauopathies. Inhibition of tau aggregation could provide a method for the treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and a stably transfected cell model to create a more physiological environment.
CITATION STYLE
Rickard, J. E., Horsley, D., Wischik, C. M., & Harrington, C. R. (2017). Assays for the screening and characterization of tau aggregation inhibitors. In Methods in Molecular Biology (Vol. 1523, pp. 129–140). Humana Press Inc. https://doi.org/10.1007/978-1-4939-6598-4_8
Mendeley helps you to discover research relevant for your work.